Luxembourg-based property company, Grand City Properties, has revised its guidance for 2023 following an increase in rental income. However, the company also reported a net loss for the second quarter, primarily driven by a devaluation of its property portfolio due to higher interest rates.

Revised Guidance for 2023

Grand City Properties now expects its funds from operations I, a key metric used to track real estate companies' bottom-line performance, to range from €175 million to €185 million this year. This is an increase from its previous expectations of €170 million to €180 million.

Net Loss in Q2

For the second quarter, the company posted a net loss of €332.6 million, compared to a profit of €169.7 million in the same period last year. The net loss can be attributed to a devaluation of the company's property portfolio, resulting in a 5.4% valuation cut on a like-for-like basis. This led to a loss of €485.8 million.

Strong Revenue Growth

Despite the net loss, Grand City Properties experienced strong revenue growth in the second quarter. The company's quarterly revenue increased to €159.3 million, up from €138.6 million in the previous year.

Decline in Funds from Operations I for H1

While the second quarter results were unfavorable, Grand City Properties saw a decline in funds from operations I for the first half of the year as a whole. The metric fell to €94.0 million from €97.2 million. However, net rental income rose by 5% to reach €204.4 million.

Tesla Unveils More Affordable Models

GE Healthcare Technologies Stock Receives a Buy Rating

Leave A Reply

Your email address will not be published. Required fields are marked *

Related posts

Custodian Property Income REIT to Acquire abrdn Property Income Trust
News

Custodian Property Income REIT to Acquire abrdn Property Income Trust

Custodian Property Income REIT announces its plan to acquire abrdn Property Income Trust through a recommended all-share...

MorphoSys Raises €102.7 Million for Drug Launch and Clinical Development
News

MorphoSys Raises €102.7 Million for Drug Launch and Clinical Development

MorphoSys raises €102.7 million to accelerate drug launch and clinical development, shares decline but still up from pos...

Cryptocurrency Market Shows Signs of Malaise
News

Cryptocurrency Market Shows Signs of Malaise

Bitcoin and other cryptocurrencies experience a decline, traders await economic data for potential market moves, low vol...

Stock Market Trends and Updates
News

Stock Market Trends and Updates

Explore the latest trends in the U.S. stock markets including winners, losers, futures outlook, commodity highlights, an...